Skip to main content

Genomic (WES), Transcriptomic (RNAseq) and Proteomic (MS) Data from 60 SEER Serous Ovarian Adenocarcinoma FFPE Tissues

File sizes do not account for external file links.
Loading, please wait.
The Surveillance, Epidemiology, and End Results (SEER) cancer registries cover approximately 28% of the United States population, providing high quality demographic, clinical, pathologic, and survival data. In three of the SEER registries, annotated FFPE tumor tissue specimens are available for research use through established Residual Tissue Repositories (RTR). WES, RNAseq, and proteomic data has been generated from these tissues. The data is available for the research community. The use of the data is flexible and may include methods development work to determine how to do proteogenomic analyses using data from FFPE tissue and comparison of proteogenomic results from TCGA fresh frozen tissue. FFPE tissues from 60 distinct cases in SEER were selected from high-grade serous ovarian adenocarcinomas (ICD-O-3 Topography code: C56.9; Morphology codes: 8441/3, 8460/3, 8461/3); duplicate tissues from 6 of those cases were also obtained as replicates. Storage time ranged from 7 to 32 years based on when tissue was resected. As specimens were retrospectively collected by the RTRs from multiple medical facilities and pathology labs within each of the three catchment areas, fixation times/conditions and storage conditions were unknown. Each SEER registry conducted a pathology review of lead and trail sections flanking the 5 sections from each tissue block to determine whether tissue was consistent with the selection criteria (high-grade serous ovarian adenocarcinoma, > 50% of cells with nuclei consistent with malignant cells, and < 50% of cells were necrotic) and NCI pathologists conducted a second review of the tissues. Additional details regarding DNA, RNA, and protein preparation are described in the relevant manuscripts.